Early-Onset ICI-Related Myocarditis Linked to Increased Mortality - Takeaways - MDSpire
Feature

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

Early-onset of immune checkpoint inhibitor (ICI)-related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Assoc...

Share

  • 1

    Early onset of myocarditis in ICI therapy increases fatality risk.

  • 2

    Critical monitoring is needed in the first month of treatment.

  • 3

    TMOS includes myocarditis, myositis, and myasthenia gravis.

  • 4

    7.8% of myocarditis patients had TMOS.

  • 5

    Higher fatalities are observed in TMOS compared to myocarditis alone.

  • 6

    XGBoost machine learning model was developed for fatality prediction.

  • 7

    Early detection helps improve treatment safety.

Original Source(s)

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality

  • by The ASCO Post Staff

  • May 4, 2026

Related Content

This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar

Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody

  • May 5, 2026

  • 5 min
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Zoldonrasib in Patients With <em>KRAS</em> G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy

The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were pr...